Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × bexmarilimab × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Colonic Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 40 Nivolumab 26 Cyclophosphamide 10 atezolizumab 9 Paclitaxel 9 Bevacizumab 9 Specimen Handling 8 Magnetic Resonance Spectroscopy 7 Ipilimumab 7 Carboplatin 7 fludarabine 6 Oxaliplatin 6 Fluorouracil 6 sargramostim 5 durvalumab 5 cabozantinib 5 avelumab 5 Sunitinib 5 Sorafenib 5 Leucovorin 5 Docetaxel 5 Cisplatin 5 aldesleukin 4 Radiosurgery 4 Irinotecan 4 Cetuximab 4 spartalizumab 3 regorafenib 3 Taxes 3 Ramucirumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05104905 2022-05-11

RENACOL

Faron Pharmaceuticals Ltd

Phase 1/2 Withdrawn

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡